



(12) Translation of  
European patent specification

(11) NO/EP 2900253 B1

NORWAY

(19) NO  
(51) Int Cl.  
**A61K 38/00 (2006.01)**  
**A61K 38/17 (2006.01)**  
**A61K 38/44 (2006.01)**  
**A61P 25/00 (2006.01)**  
**C12N 9/02 (2006.01)**

**Norwegian Industrial Property Office**

---

|      |                                                                            |                                                                                                                                                                                                   |
|------|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (21) | Translation Published                                                      | 2019.05.06                                                                                                                                                                                        |
| (80) | Date of The European<br>Patent Office Publication of<br>the Granted Patent | 2018.11.14                                                                                                                                                                                        |
| (86) | European Application Nr.                                                   | 13841917.1                                                                                                                                                                                        |
| (86) | European Filing Date                                                       | 2013.09.27                                                                                                                                                                                        |
| (87) | The European Application's<br>Publication Date                             | 2015.08.05                                                                                                                                                                                        |
| (30) | Priority                                                                   | 2012.09.27, US, 201261706615 P                                                                                                                                                                    |
| (84) | Designated Contracting<br>States:                                          | AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ;<br>IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ;<br>SK ; SM ; TR |
| (73) | Proprietor                                                                 | Quincy Bioscience, LLC, 301 South Westfield Road, Suite 200, Madison, WI 53717,<br>USA                                                                                                            |
| (72) | Inventor                                                                   | UNDERWOOD, Mark, Y., 7645 Sawmill Road, Madison, WI 53717, USA                                                                                                                                    |
| (74) | Agent or Attorney                                                          | ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge                                                                                                                                             |

---

|      |       |                                                                                                                |
|------|-------|----------------------------------------------------------------------------------------------------------------|
| (54) | Title | <b>METHODS FOR ALLEVIATING SYMPTOMS OF MULTIPLE SCLEROSIS BASED ON<br/>APOAEQUORIN-CONTAINING COMPOSITIONS</b> |
|------|-------|----------------------------------------------------------------------------------------------------------------|

|      |                      |                                                                                                                                                                                                                                                                                                                  |
|------|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (56) | References<br>Cited: | WO-A1-2012/022740, US-A1- 2008 293 092, 'Quincy bioscience puts hope in walk for multiple<br>sclerosis' PRWEB NEWSWIRE 29 April 2011, XP055249239 Retrieved from the Internet:<br><URL:http://search.proquest.com/professiona l/docview/864500341?accountid=157282>,<br>US-A1- 2011 130 336, US-A1- 2011 124 562 |
|------|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

**Patentkrav**

- 5       **1.** Apoeaquorin for anvendelse til lindring av et symptom som er assosiert med  
multipel sklerose, hos et individ,  
hvor i apoeaquorinet er formulert som en oral dose omfattende apoeaquorinet og  
en bærer,  
hvor i 40 mg til 80 mg av apoeaquorinet er inneholdt i den orale dosen,  
hvor i fortrinnsvis omtrent 40 mg av apoeaquorinet er inneholdt i den orale dosen.
- 10       **2.** Apoeaquorinet for anvendelse ifølge krav 1, hvor i symptomet som er assosiert  
med multipel sklerose er, redusert søvnkvalitet, redusert energi, redusert humør,  
 redusert kognitiv funksjon eller smerte.